Testing SIPA1L2 as a modifier of CMT1A using mouse models.

J Neuropathol Exp Neurol

The Jackson Laboratory, Bar Harbor, Maine, USA.

Published: April 2024

Charcot-Marie-Tooth disease type 1A (CMT1A) is a demyelinating peripheral neuropathy caused by the duplication of peripheral myelin protein 22 (PMP22), leading to muscle weakness and loss of sensation in the hands and feet. A recent case-only genome-wide association study of CMT1A patients conducted by the Inherited Neuropathy Consortium identified a strong association between strength of foot dorsiflexion and variants in signal induced proliferation associated 1 like 2 (SIPA1L2), indicating that it may be a genetic modifier of disease. To validate SIPA1L2 as a candidate modifier and to assess its potential as a therapeutic target, we engineered mice with deletion of exon 1 (including the start codon) of the Sipa1l2 gene and crossed them to the C3-PMP22 mouse model of CMT1A. Neuromuscular phenotyping showed that Sipa1l2 deletion in C3-PMP22 mice preserved muscular endurance assayed by inverted wire hang duration and changed femoral nerve axon morphometrics such as myelin thickness. Gene expression changes suggest involvement of Sipa1l2 in cholesterol biosynthesis, a pathway that is also implicated in C3-PMP22 mice. Although Sipa1l2 deletion did impact CMT1A-associated phenotypes, thereby validating a genetic interaction, the overall effect on neuropathy was mild.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11029467PMC
http://dx.doi.org/10.1093/jnen/nlae020DOI Listing

Publication Analysis

Top Keywords

sipa1l2 deletion
8
c3-pmp22 mice
8
sipa1l2
6
testing sipa1l2
4
sipa1l2 modifier
4
cmt1a
4
modifier cmt1a
4
cmt1a mouse
4
mouse models
4
models charcot-marie-tooth
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!